Aadi Bioscience is a biotechnology company focused on improving the lives of people with mTOR-driven diseases. Its approach combines research into the mTOR pathway with precision medicine, aiming to address limitations of existing mTOR inhibitors and use genomic profiling to identify patients most likely to benefit from treatment. The company also highlights albumin-bound nanoparticle, or nab, technology as part of its scientific platform.

Aadi’s work includes a medicine program for advanced malignant PEComa, alongside a broader pipeline of investigational therapies. Its website provides information about the company’s science, technology platform, publications and research abstracts, as well as details for patients and healthcare professionals. Aadi also offers information about expanded access and patient advocacy, and provides channels for general inquiries and career opportunities. Through its focus on mTOR biology, patient selection and nanoparticle-based drug technology, Aadi Bioscience seeks to advance treatment options for people affected by diseases driven by this pathway. The company cautions job seekers to verify opportunities through its official careers page.